New Update | Shengshi Taikang Secures First Tranche of Over 100 Million Yuan in Series C Funding, Kicking Off the Commercialization Journey for Its Core Innovative Products

Clinical results show that, compared to existing similar drugs on the market, this one delivers "double the efficacy at half the dose," positioning it as a potentially top-tier glucose-lowering medication in its class. Even more remarkable is its enhanced safety profile, effectively addressing the common adverse reactions often observed with currently available products.

Shengshi Taikе is a biotechnology company in the commercialization phase, with a core team boasting decades of international experience across the entire lifecycle of pharmaceutical products. The company is dedicated to the research, development, and industrialization of high-quality, differentiated small-molecule innovative drugs. Leveraging an integrated drug R&D technology platform and a diverse business perspective, Shengshi Taikе has built a robust pipeline of cutting-edge therapies spanning areas such as blood sugar control, cancer treatment, and autoimmune diseases.

Currently, The company's newly developed, next-generation, highly selective DPP-4 inhibitor—sengliflozin—is soon set to receive regulatory approval and launch on the market. Clinical results indicate that, compared to existing同类 drugs on the market, this one delivers "double the efficacy with half the dose," positioning it as a potentially top-tier glucose-lowering medication in its class. Even more remarkable is its enhanced safety profile, effectively addressing the common adverse reactions often seen with currently available products.

The successful development of sotagliflozin has validated the innovation and feasibility of the company's R&D platform. Leveraging this platform, the company has also developed several oncology drugs that have advanced into clinical stages—among them, the CXCR4 antagonist CGT-1881, which is used for hematopoietic stem cell mobilization. The country's only original small-molecule oral CXCR4 antagonist ; The dual FGFR/VEGFR inhibitor CGT-6321 holds promise as a potential "first-in-class" drug in the treatment of solid tumors. Among these products, two drugs have already received clinical trial approval from the U.S. FDA, and this round of funding will further accelerate the company’s efforts to innovate and expand globally.

In today’s biopharmaceutical landscape, Shengshi Taikang has defied the trend by securing over 100 million yuan in funding, highlighting investors’ strong confidence in the company’s innovation and industrialization capabilities. You Ronghui, Partner at Tongren Boda, the lead investor in this round, commented: "As China’s population ages and its economic standards continue to rise, We are highly optimistic about the growth prospects in areas such as metabolism and oncology, particularly in the diabetes drug market. As the region with the largest number of diabetes patients, China has a strong demand for innovative therapies that offer superior efficacy and enhanced safety. "At this critical moment as the company's core product prepares for market launch, we believe this round of funding will help the enterprise smoothly embark on its commercialization journey and accelerate the development of other innovative products, paving the way for a new chapter in the company's growth."